Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Aurinia Pharmaceuticals (AUPH) Misses Q4 EPS by 2c

Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights

March 19, 2019 4:02 PM EDT

VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars.

2018 and Recent Highlights

Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims which have the potential to cover voclosporins method of use and dosing protocol for lupus nephritis (LN) until December 2037. Phase 2a Dry Eye Study results released in January 2019 demonstrating statistically superior efficacy of... More